Kuruva Siva Prasad, Bala Stalin, Konatam Meher Lakshmi, Karnam Ashok Kumar, Maddali Lakshmi Srinivas, Gundeti Sadashuivudu
Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
South Asian J Cancer. 2018 Oct-Dec;7(4):270-272. doi: 10.4103/sajc.sajc_269_17.
Synovial sarcoma (SS) is a malignant mesenchymal tumor. It is most common among children and adults. The data on SS from India are scarce. In this study, we analyzed the clinicopathological treatment parameters and survival outcomes of SS patients.
A total of 57 histologically proven SS diagnosed from 2010 to 2016 were retrospectively analyzed.
The median age was 23 years with a male-to-female ratio of 1.28:1. Localized disease was seen in 44 patients (77%) and 13 patients (23%) had metastasis. The primary sites of involvement such as lower limb, upper limb, thorax, and abdomen were seen in 60%, 28%, 7%, and 5% patients, respectively. Surgery was done in 39 patients and 18 patients had unresectable disease. Adjuvant chemotherapy with doxorubicin-based regimen was given in 30 patients and adjuvant radiotherapy in 21 patients. Palliative chemotherapy with anthracycline-based or gemcitabine-based regimen was used in 17 and 2 patients, respectively. The median event-free survival (EFS) was 30 months with 3 years and EFS rate was 36%; median progression-free survival (PFS) was 11.5 months and 1 year; and PFS rate was 38%. On univariate analysis, resection and performance status were significantly associated with survival. There is no impact of grade and size of the tumor on survival. In metastatic patients, the lung is the most common site.
SS is the most common soft-tissue sarcoma among adults. Resectability and performance status were impacting the survival.
滑膜肉瘤（SS）是一种恶性间叶组织肿瘤。它在儿童和成人中最为常见。来自印度的滑膜肉瘤数据稀缺。在本研究中，我们分析了滑膜肉瘤患者的临床病理治疗参数及生存结果。
回顾性分析了2010年至2016年间共57例经组织学证实的滑膜肉瘤。
中位年龄为23岁，男女比例为1.28:1。44例患者（77%）为局限性疾病，13例患者（23%）发生转移。受累的主要部位如下肢、上肢、胸部和腹部，分别见于60%、28%、7%和5%的患者。39例患者接受了手术，18例患者有不可切除的疾病。30例患者接受了以阿霉素为基础方案的辅助化疗，21例患者接受了辅助放疗。分别有17例和2例患者接受了以蒽环类或吉西他滨为基础方案的姑息化疗。中位无事件生存期（EFS）为30个月，3年EFS率为36%；中位无进展生存期（PFS）为11.5个月，1年PFS率为38%。单因素分析显示，切除和体能状态与生存显著相关。肿瘤分级和大小对生存无影响。在转移患者中，肺是最常见的转移部位。
滑膜肉瘤是成人中最常见的软组织肉瘤。可切除性和体能状态影响生存。
